Healthcare in the Dutch startup scene counts 78 players and a growing AI core

The Dutch healthcare and health sector is home to at least 78 startups in 2026 that apply technology, and frequently AI, to diagnostics, hospital logistics, prevention and home care. Most of these companies are based in Amsterdam, but Rotterdam, Nijmegen, Groningen and Utrecht are also represented. Together they have raised tens of millions of euros, though funding amounts vary considerably.

What stands out in the current landscape is the breadth of applications. Whereas early healthtech startups often confined themselves to apps or patient portals, the current generation focuses on clinical workflows, early diagnostics and elderly care. AI is no longer a distinguishing feature in this context, but a standard component of the approach.

Early diagnostics attracts the most attention and the most money

A distinct cluster within the sector focuses on diagnosing conditions earlier and more accurately. Screenpoint Medical, based in Nijmegen, develops AI software that helps radiologists detect breast cancer via mammograms; the company raised a Series B of €27 million in 2023. Aidence, based in Rotterdam, focuses on detecting lung nodules in CT scans and has received a total of €13.2 million. SkinVision, founded in 2011 and one of the older names in this segment, offers a clinically validated app that allows users to identify skin cancer and has raised €11 million in a Series B round.

Nostics, founded in Amsterdam in 2020, takes a different approach. The company is developing a method to identify bacterial infections in fewer than ten minutes directly on-site, which is relevant for both GP practices and hospitals. Nostics has so far received €10 million in seed funding.

All of these companies operate in a market where the technology is ready, but the path to broad clinical implementation takes time. Certification under the European MDR regulation and integration with existing hospital systems require substantial investment, separate from the technological development itself.

Hospital logistics and clinical support form a second pillar

Alongside diagnostics, part of the sector focuses on the organisation of care within institutions. Kaiko, founded in Amsterdam in 2021, is building an AI assistant that supports clinicians in ongoing clinical workflows. The company had already raised €82.5 million in a Series B round in 2022, making it one of the best-funded healthcare AI companies in the Netherlands.

Pacmed, also from Amsterdam and founded in 2014, develops an AI platform that helps hospitals optimise intensive care unit capacity and improve patient outcomes. In 2021 it closed a Series A of €24 million. The ICU challenges that came into sharp focus during the COVID-19 pandemic have created a structural demand for this type of solution.

Home care and prevention target the elderly and vulnerable groups

A third direction within the sector revolves around care outside the hospital. Sensara, based in Rotterdam, develops smart sensors that monitor the health and safety of elderly people at home and in care homes; the company was founded in 2013 and has completed a Series A of €9 million. Ancora Health, based in Groningen, offers a digital platform for prevention, rehabilitation and remote care and has also raised €9 million.

Notable is the entry of iseeubabycare, founded in Utrecht in 2024. This company measures sleep in premature babies objectively via an AI camera system. In 2025 it raised €27 million in a venture round, an unusually large financing round for such a young company. That amount reflects the anticipated market potential of neonatal monitoring, a segment that has traditionally received little technological attention.

Funding is concentrated among a small group

The funding data show a skewed distribution. Kaiko (€82.5 million) and the energy companies Sympower (€74.5 million) and Overstory (€67.8 million), which are included in the database but fall primarily outside healthcare, stand well above the average. Within the pure healthcare sector, Screenpoint Medical and iseeubabycare follow with €27 million each, succeeded by Pacmed with €24 million and Antonie with €18.4 million.

Most other companies are at a seed or early Series A stage with amounts between €9 million and €13 million. This pattern is recognisable for a sector where long lead times for validation and certification raise the risk profile for investors. Late-stage capital therefore remains scarce.

Adoption, regulation and data remain structural bottlenecks

Despite the technological maturity of many solutions, adoption in healthcare lags behind. Hospitals and care institutions operate with outdated IT infrastructure, complex procurement processes and risk-averse policies. The result is that many products are CE-certified but in practice deployed at only a limited number of institutions.

Regulation under the European AI Act adds an additional layer. Medical AI applications fall into higher risk categories and must meet stringent transparency and documentation requirements. For startups with limited legal capacity, this represents a considerable burden.

A third bottleneck is the availability and quality of data. Training and validating medical AI models requires large, well-labelled datasets. Privacy legislation, fragmented systems and the absence of national data-sharing agreements make this difficult. Initiatives such as Health-RI offer starting points, but a structured national approach is still lacking.

For founders and investors in this segment, this means that technological quality is a necessary but not sufficient condition. Companies that succeed in engaging hospitals or health insurers early as partners build a lead that is difficult to close. The European market offers scale, but the routes there almost always run through national healthcare systems, each with their own procurement and reimbursement logic.